Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Met deze maand de aandeelhoudersvergadering en ex dividend
Klopt het dat er na 26 mei geen aandeel meer gekocht en verkocht is!!! Wat zegt dit voor de cijfers deze maand!!
Lang lang geleden zou je het antwoord " we gaan knallen!!" hebben gekregen. Weet niet meer wie dit was maar was wel een zeer positief ingestelde aandeelhouder. Ik wacht het rustig af. Groet ABC
Tja ik heb me ook wel eens verloren in te rooskleurig denken, misschien is het altijd die hoop dat er iets spectaculairs gebeurt en dat je die koers richting die 15 pond ziet gaan. Dus blijf ik rustig zitten en hopen op dit scenario!
Gartje, Deze dan, leuke uitbreiding toch van onze klant 3M:www.londonstockexchange.com/news-arti...
Hier doen we het voor ABC;-))
Hier nog even het bericht van Sopheon zelf:Sopheon Announces Global Deployment of Enterprise Innovation Management Solution at The 3M Company 3M manages its global portfolio of innovation and growth initiatives using Sopheon Accolade® Sopheon has today announced that The 3M Company (NYSE: MMM) a long-standing customer of the group, is using its Accolade software for new product development throughout its global enterprise. 3M’s cross-functional innovation teams rely on Sopheon Accolade to streamline processes, manage risk, optimize decision-making and accelerate time to market. 3M produces over 60,000 products under several brands and is a leader in consumer products, safety and industrial, healthcare, transportation, and electronics. 3M’s deployment of Sopheon Accolade is enterprise-wide, including every division and business group across the company. This implementation involves thousands of users at all levels of the business, including research and development (R&D) scientists and researchers, manufacturing, supply chain, finance, sales and marketing, as well as commercialization managers and senior executives.“R&D is the heartbeat of 3M,” said Elizabeth Edblom, Ph.D., Director, Corporate Research & Development Global Strategy and New Growth at 3M. “Innovation is the thread that connects our four business groups to the vast amount of science conducted by the thousands of scientists and researchers we have around the world. The unprecedented enterprise-wide transparency provided by the Sopheon Accolade platform allows us to know what’s going on in new product commercialization before, during and after launch. Additionally, Accolade’s unique portfolio management capabilities provide business leaders with planning and performance insights required to govern the millions of dollars 3M invests in innovation. Finally, 3M is proud of our Sustainability Value Commitment for all new products – and Sopheon Accolade helps make that possible.” Accolade is Sopheon’s award-winning innovation management platform that connects people, systems and information across departments and functions. This collaboration and synchronization results in trusted, timely data for faster, better and more dynamic decision making. In addition to 3M, Sopheon Accolade has proven its value to thousands of other global users, such as Honeywell, Merck KGaA, P&G, Philips, BASF, Parker Hannifin and other innovation and market leaders across a wide variety of industries.“3M’s commitment to innovation is extraordinary,” said Greg Coticchia, CEO, Sopheon. “With 8,000 scientists and researchers working on 51 technology platforms in 650 different countries, it’s essential that they have a global system that allows engagement and visibility among all functions. In addition to enabling the alignment of strategy and execution, the configurability of Accolade allowed 3M to deploy a system that ensures the organization remains focused on outcomes and not processes.” For further information contact: Andy Michuda, (Executive Chairman) Arif Karimjee, (CFO) Sopheon plc + 44 (0) 1276 919 560www.sopheon.com/sopheon-announces-glo... Bertus S.
RNS Number : 7668A Sopheon PLC 03 June 2021 SOPHEON PLC ("Sopheon" or the "Company") Issue of Equity - Option Exercise Sopheon plc, an international global leader in enterprise innovation management solutions, announces that, following the exercise of options by a former employee, it has issued and allotted 15,415 new Ordinary Shares of 20 pence each in the Company ("Ordinary Shares"). Application will be made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 10 June 2021. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares. The total number of Ordinary Shares in issue following Admission will be 10,468,903. The Company does not hold any shares in treasury. Accordingly, the figure of 10,468,903 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
Wat denken jullie, morgen ivm de AVA nog een update over de business door de nieuwe voorzitter?
tritace schreef op 9 juni 2021 20:52 :
Wat denken jullie, morgen ivm de AVA nog een update over de business door de nieuwe voorzitter?
Ja. Groet ABC
Ik denk dat hij best goed zal zijn. De nieuwe voorzitter zal willen beginnen met een goed nieuws show neem ik aan. Suc6 Trinko
www.londonstockexchange.com/news-arti... Sopheon, the international provider of software, expertise, and best practices for enterprise innovation management solutions, holds its Annual General Meeting ("AGM") today. Given the Coronavirus situation, Shareholders are not expected to attend the meeting in person, and were encouraged in the notice to submit a proxy vote. The Board takes this opportunity to give shareholders the following update and review of the business. 2020 in review We were proud to report a growth in contractual bookings in a year of unpredictability and unparalleled disruption. Revenue at $30m matched 2019, showing resilience, and several transformational indicators showed rising commercial traction, even in the face of two separate headwinds - the pandemic introduced new challenges to sales and retention; and our strategy to make selling new SaaS contracts a priority. Transition to SaaS contracts reduces revenue recognition in the first year compared to traditional perpetual licenses, trading this for a higher quality and predictable ongoing recurring revenue stream in the future. In spite of these challenges, Total Contract Value (TCV) of sales booked in the year was up almost a quarter, and we nearly tripled the TCV of new SaaS contracts booked. Six of the new deals signed exceeded $1m in initial TCV, and Annual Recurring Revenue (ARR) closed at $18m, an historic high up from $15.9m a year ago. As always, much of this activity concentrated into the fourth quarter. Retention was impacted during the initial stages of the pandemic, then rebounded later in the year. We achieved this while delivering a solidly profitable and cash generative year, also reporting new highs in cash balances and closing net assets. In parallel, we embarked on the development of new cloud-native products, which will bring value to personal and workgroup productivity alongside the corporate value points we are well known for. In addition, in early 2021, we introduced new leadership with the appointment of Greg Coticchia as CEO, Andy Michuda moving to the executive chairman role with a particular focus on partnerships and acquisitions, and Barry Mence stepping back to become a non-executive director. Our dividend was maintained at 3.25p per share, and is proposed to shareholders in today's meeting. Operational update Since the start of the year, under Greg's leadership we have continued to execute on our transformational strategy. This is exemplified by the recent appointments of Mike Bauer as Chief Product Officer, John Beischer as Americas VP of Sales, and Ann Marie Beasley as Chief Marketing Officer. Each one of these appointees bring an impressive track record and their experience, creativity, and drive will be valuable assets to Sopheon during this exciting period of transformation and growth. Mike has introduced over 100 products to market in his career, and offers deep experience in creating cloud-based solutions working across a range of companies, from start up to established enterprise such as Avnet and 3Com. John has led transformation efforts at various companies, from emerging enterprises to industry powerhouses like IBM and has an impressive record of creating and expanding industry leading go-to-market distribution channels in competitive and complex marketplaces. Ann Marie boasts an exceptional track record for developing and executing successful marketing strategies at companies like Allscripts, CA Technologies and Symantec. Another milestone was the launch of Accolade® for Smart Products, the first innovation management solution to bring together traditionally siloed software and physical product development - a new SaaS-based solution that enables companies to develop innovative digitally-enabled physical products in a new collaborative and efficient way with speed. Outlook We are pleased to report 27 software transactions closed so far this year, of which just under half were SaaS related. So far these have been mainly customer extension deals and smaller in size - metrics we expect to balance out through the year as normal with some new and larger deals in the pipeline. Customer retention has been strong; and coupled with new orders, ARR has risen above $19m compared to $18m at the end of 2020. Visibility for the full year 2021 now stands at $28m, compared to $23.2m at the time of our AGM announcement last year, which is very encouraging. In parallel with this continued evidence of commercial traction, we continue to see a strong appetite for innovation solutions. With our new senior appointments, we are undertaking a detailed review of our sales pipelines as companies work to find the new norm of conducting business post Covid. We are already seeing the benefits of alternative approaches and fresh ideas. Net cash at the end of May was $23.3m (2020: $21.3m), though a seasonal peak always occurs this time of year, it underlines our financial strength. These commercial and financial proof points give us the confidence to proceed with our strategy both in terms of operational expansion - we continue to hire and invest for growth - and with continuing our search of the right M&A candidates.
Visible inmiddels 28 Netjes hoor
Ziet er keurig uit vind ik. Deze visible had ik nooit verwacht. Mooie opmaat voor hogere koersen. Gr Arie de Beuker
Volgens Finncap Sopheon* AGM statement and positive trading update Sopheon has reported a positive trading update for the period to date, including strong core KPIs: revenue visibility for the year of a record $28m for this time of year (85% of full-year forecasts, vs 77% covered this time last year, showing the benefit of increasing levels of SaaS revenue) and ARR of $19m, up from $18m since FY20 and +15% from $16.5m at 1H20. 27 deals (1H20: 13) include the typical modern mix of 50% SaaS, but mostly smaller extensions, with a still strong pipeline of new larger deals. With several senior appointments in addition to the March appointment of CEO Greg Coticchia, the balance sheet supports the strategic choices for the group, at a seasonal high cash position of $23.3m at the end of May, in line with FY expectations. We look forward to continued evidence of commercial traction, and reiterate our 1200p target price (4.2x FY22 EV/Sales).
De koers valt me tegen, dus maar weer teren op mijn aow;-)
Gartje, ik vind de huidige visible erg positief, als het meezit gaat de omzet richting 36 a 38 miljoen Dit jaar. Gr Arie de Beuker
Zou kunnen Arie, maar ik ben wat voorzichtiger; schat zelf 34/35. Vind overigens de reacties, incl. die van de koers, erg behoudend Omzet bij de koers een ruime 5000 op dit moment. Ik vond het een keurig eerste bericht van de nieuwe voorzitter. To the point en ter zake doend. Eens kijken wat augustus voor visible te melden heeft, dat zal wat meer richting geven.
De tijden dat je op goede vooruitzichten en cijfers 10 tot 15 procent stijgt lijkt voorbij, dan moet ik wel denken aan de woorden van Trinko dat de echte koersgroei er een beetje uit is. Dat ze een goede ontwikkeling laten zien staat buiten kijf!! Dus ik wacht dus rustig op de 12 pond.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
891,13
+0,42%
EUR/USD
1,0773
+0,08%
FTSE 100
8.213,49
+0,51%
Germany40^
18.209,00
+1,15%
Gold spot
2.324,47
+0,99%
NY-Nasdaq Composite
16.156,33
+1,99%
Stijgers
Dalers